Intestinal microbiome analysis revealed dysbiosis in sickle cell disease

REFERENCES [1] Duarte FB, Barbosa MC, Jesus Dos Santos TE, et al. Bone marrow fibrosis at diagnosis is associated with TP53 overexpression and adverse prognosis in low-risk myelodysplastic syndrome. Br J Haematol. In press. https://doi.org/10.1111/bjh.14656. [2] Dolgikh TY, Domnikova NP, Tornuev YV, Vinogradova EV, Krinitsyna YM. Incidence of myelofibrosis in chronic myeloid leukemia, multiple myeloma, and chronic lymphoid leukemia during various phases of diseases. Bull Exp Biol Med. 2017;162(4):483–487. [3] Barcellini W, Fattizzo B, Zaninoni A, et al. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood. 2014;124(19):2930– 2936. [4] Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. [5] Barcellini W, Fattizzo B, Zaninoni A, et al. Clinical evolution of autoimmune cytopenias to idiopathic cytopenias/dysplasias of uncertain significance (ICUS/IDUS) and bone marrow failure syndromes. Am J Hematol. 2017;92(3):E26–E29. [6] Mies A, Hermine O, Platzbecker U. Activin receptor II ligand traps and their therapeutic potential in myelodysplastic syndromes with ring sideroblasts. Curr Hematol Malign Rep. 2016;11(6):416–424.